Year Founded
2015
Ownership
Private
Employees
~10
Stage
Phase 1
Modalities
Multispecific monoclonal antibodyAntibody-based immunotherapy

CytoCares General Information

CC312 (CD19/CD3/CD28 trispecific antibody) received FDA IND clearance and showed significant efficacy and safety in preclinical studies for hematological tumors

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office

Drug Pipeline

CC312
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to CytoCares's pipeline data

Book a demo

Key Partnerships

Medicilon

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CytoCares Funding

Deal TypeDateAmountStatusStage
Later Stage VCMay 13, 2023$14.4MCompletedPhase 1
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view CytoCares's complete valuation and funding history, request access »